For the quarter ending 2025-09-30, SIGY had $85,112 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -578,503 | -2,119,751 |
| Depreciation expense | 0 | 1,363 |
| Stock based compensation | 50,000 | 100,000 |
| Accretion of debt discount | -70,211 | -69,879 |
| Accretion of original issuance costs | 119,739 | 175,370 |
| Modification of warrants | 0 | 17,505 |
| Inducement of preferred shares | 0 | 845,901 |
| Settlement of lease | 0 | 5,798 |
| Other current assets | -1,300 | -7,697 |
| Other assets | 0 | -20,711 |
| Accounts payable | 43,758 | 121,462 |
| Accrued payroll and payroll taxes | 93,645 | 317,113 |
| Other current liabilities | 524 | 1,666 |
| Net cash used in operating activities | -199,326 | -446,882 |
| Advance from shareholder | - | 0 |
| Repayments of advance from shareholder | - | 0 |
| Proceeds from short-term convertible notes | 281,438 | 425,197 |
| Proceeds from short-term promissory notes | 3,000 | 10,000 |
| Net cash provided by financing activities | 284,438 | 435,197 |
| Net increase in cash | 85,112 | -11,685 |
| Cash and cash equivalents at beginning of period | 12,144 | - |
| Cash and cash equivalents at end of period | 85,571 | - |
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)